Omeros PE Ratio 2010-2024 | OMER
Current and historical p/e ratio for Omeros (OMER) from 2010 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Omeros PE ratio as of May 07, 2025 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Omeros PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2025-05-07 | 6.35 | 0.00 | |
| 2024-12-31 | 9.88 | $-2.70 | 0.00 |
| 2024-09-30 | 3.97 | $-2.31 | 0.00 |
| 2024-06-30 | 4.06 | $-2.35 | 0.00 |
| 2024-03-31 | 3.45 | $-1.97 | 0.00 |
| 2023-12-31 | 3.27 | $-1.88 | 0.00 |
| 2023-09-30 | 2.92 | $0.32 | 9.13 |
| 2023-06-30 | 5.44 | $0.64 | 8.50 |
| 2023-03-31 | 4.65 | $0.74 | 6.28 |
| 2022-12-31 | 2.26 | $0.75 | 3.01 |
| 2022-09-30 | 3.15 | $3.18 | 0.99 |
| 2022-06-30 | 2.75 | $3.10 | 0.89 |
| 2022-03-31 | 6.01 | $3.13 | 1.92 |
| 2021-12-31 | 6.43 | $3.09 | 2.08 |
| 2021-09-30 | 13.79 | $-1.99 | 0.00 |
| 2021-06-30 | 14.84 | $-2.29 | 0.00 |
| 2021-03-31 | 17.80 | $-2.44 | 0.00 |
| 2020-12-31 | 14.29 | $-2.40 | 0.00 |
| 2020-09-30 | 10.11 | $-2.38 | 0.00 |
| 2020-06-30 | 14.72 | $-2.05 | 0.00 |
| 2020-03-31 | 13.37 | $-1.73 | 0.00 |
| 2019-12-31 | 14.09 | $-1.70 | 0.00 |
| 2019-09-30 | 16.33 | $-1.60 | 0.00 |
| 2019-06-30 | 15.69 | $-2.08 | 0.00 |
| 2019-03-31 | 17.37 | $-2.49 | 0.00 |
| 2018-12-31 | 11.14 | $-2.61 | 0.00 |
| 2018-09-30 | 24.41 | $-2.47 | 0.00 |
| 2018-06-30 | 18.14 | $-1.82 | 0.00 |
| 2018-03-31 | 11.17 | $-1.45 | 0.00 |
| 2017-12-31 | 19.43 | $-1.17 | 0.00 |
| 2017-09-30 | 21.62 | $-1.28 | 0.00 |
| 2017-06-30 | 19.91 | $-1.46 | 0.00 |
| 2017-03-31 | 15.12 | $-1.45 | 0.00 |
| 2016-12-31 | 9.92 | $-1.65 | 0.00 |
| 2016-09-30 | 11.16 | $-1.72 | 0.00 |
| 2016-06-30 | 10.52 | $-1.91 | 0.00 |
| 2016-03-31 | 15.34 | $-2.03 | 0.00 |
| 2015-12-31 | 15.73 | $-2.00 | 0.00 |
| 2015-09-30 | 10.96 | $-2.09 | 0.00 |
| 2015-06-30 | 17.99 | $-2.10 | 0.00 |
| 2015-03-31 | 22.03 | $-2.19 | 0.00 |
| 2014-12-31 | 24.78 | $-2.22 | 0.00 |
| 2014-09-30 | 12.72 | $-1.66 | 0.00 |
| 2014-06-30 | 17.40 | $-1.58 | 0.00 |
| 2014-03-31 | 12.07 | $-1.53 | 0.00 |
| 2013-12-31 | 11.29 | $-1.39 | 0.00 |
| 2013-09-30 | 9.75 | $-1.64 | 0.00 |
| 2013-06-30 | 5.04 | $-1.69 | 0.00 |
| 2013-03-31 | 4.12 | $-1.59 | 0.00 |
| 2012-12-31 | 5.19 | $-1.59 | 0.00 |
| 2012-09-30 | 9.40 | $-1.75 | 0.00 |
| 2012-06-30 | 10.00 | $-1.53 | 0.00 |
| 2012-03-31 | 9.93 | $-1.39 | 0.00 |
| 2011-12-31 | 3.95 | $-1.29 | 0.00 |
| 2011-09-30 | 4.05 | $-1.17 | 0.00 |
| 2011-06-30 | 4.12 | $-1.23 | 0.00 |
| 2011-03-31 | 8.00 | $-1.35 | 0.00 |
| 2010-12-31 | 8.24 | $-1.36 | 0.00 |
| 2010-09-30 | 7.29 | $-1.30 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.370B | $0.000B |
| Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $231.503B | 27.84 |
| Boston Scientific (BSX) | United States | $154.040B | 38.56 |
| Stryker (SYK) | United States | $144.095B | 30.13 |
| EssilorLuxottica (ESLOY) | France | $132.622B | 0.00 |
| Medtronic (MDT) | Ireland | $105.579B | 15.42 |
| Lonza Group Ag (LZAGY) | Switzerland | $51.866B | 0.00 |
| Haleon (HLN) | United Kingdom | $48.124B | 27.36 |
| ResMed (RMD) | United States | $35.477B | 26.65 |
| GE HealthCare Technologies (GEHC) | United States | $30.720B | 14.59 |
| Agilent Technologies (A) | United States | $30.004B | 19.82 |
| Terumo (TRUMY) | Japan | $29.197B | 0.00 |
| Koninklijke Philips (PHG) | Netherlands | $22.643B | 16.28 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.255B | 11.72 |
| Insulet (PODD) | United States | $18.215B | 77.74 |
| Baxter (BAX) | United States | $15.352B | 11.47 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $12.456B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $9.032B | 0.00 |
| Demant (WILYY) | Denmark | $7.970B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $7.179B | 17.65 |
| Bio-Rad Laboratories (BIO) | United States | $6.487B | 21.93 |
| Prestige Consumer Healthcare (PBH) | United States | $4.014B | 19.16 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Perrigo (PRGO) | Ireland | $3.368B | 9.64 |
| ICU Medical (ICUI) | United States | $3.306B | 28.16 |
| Haemonetics (HAE) | United States | $3.194B | 15.03 |
| Envista Holdings (NVST) | United States | $2.778B | 23.08 |
| GN Store Nord (GNNDY) | Denmark | $2.069B | 17.14 |
| LeMaitre Vascular (LMAT) | United States | $1.855B | 41.46 |
| QuidelOrtho (QDEL) | United States | $1.750B | 14.65 |
| AtriCure (ATRC) | United States | $1.478B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.281B | 20.17 |
| AdaptHealth (AHCO) | United States | $1.194B | 12.12 |
| Neogen (NEOG) | United States | $1.192B | 15.25 |
| Kestra Medical Technologies (KMTS) | United States | $1.139B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.043B | 0.00 |
| InMode (INMD) | Israel | $0.995B | 9.11 |
| Phibro Animal Health (PAHC) | United States | $0.771B | 11.83 |
| Evolus (EOLS) | United States | $0.749B | 0.00 |
| Owens & Minor (OMI) | United States | $0.596B | 5.07 |
| Curaleaf Holdings (CURLF) | Canada | $0.579B | 0.00 |
| CeriBell (CBLL) | United States | $0.568B | 0.00 |
| Valneva SE (VALN) | France | $0.542B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.518B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.424B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.420B | 0.00 |
| Surmodics (SRDX) | United States | $0.391B | 0.00 |
| SNDL (SNDL) | Canada | $0.344B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.340B | 14.75 |
| Capricor Therapeutics (CAPR) | United States | $0.333B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.317B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.302B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.292B | 26.43 |
| Sanara MedTech (SMTI) | United States | $0.283B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.262B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.259B | 46.10 |
| ZimVie (ZIMV) | United States | $0.245B | 14.65 |
| Cerus (CERS) | United States | $0.239B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.235B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.217B | 0.00 |
| Quanterix (QTRX) | United States | $0.208B | 0.00 |
| High Tide (HITI) | Canada | $0.192B | 0.00 |
| Biote (BTMD) | United States | $0.184B | 4.21 |
| Utah Medical Products (UTMD) | United States | $0.176B | 14.16 |
| TriSalus Life Sciences (TLSI) | United States | $0.166B | 0.00 |
| Brainsway (BWAY) | Israel | $0.162B | 50.65 |
| Organigram Global (OGI) | Canada | $0.147B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.146B | 17.99 |
| Jin Medical (ZJYL) | China | $0.130B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.117B | 0.00 |
| Exagen (XGN) | United States | $0.116B | 0.00 |
| Agape ATP (ATPC) | $0.103B | 0.00 | |
| MacroGenics (MGNX) | United States | $0.093B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.091B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.091B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.086B | 0.00 |
| Fonar (FONR) | United States | $0.076B | 10.58 |
| Veru (VERU) | United States | $0.074B | 0.00 |
| InterCure (INCR) | Israel | $0.073B | 0.00 |
| Zynex (ZYXI) | United States | $0.061B | 0.00 |
| United Health Products (UEEC) | United States | $0.059B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.056B | 0.00 |
| ImmuCell (ICCC) | United States | $0.046B | 0.00 |
| Modular Medical (MODD) | United States | $0.041B | 0.00 |
| Apyx Medical (APYX) | United States | $0.040B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.038B | 55.50 |
| Safety Shot (SHOT) | United States | $0.037B | 0.00 |
| United-Guardian (UG) | United States | $0.036B | 11.14 |
| Nephros (NEPH) | United States | $0.019B | 0.00 |
| INLIF (INLF) | $0.017B | 0.00 | |
| Trinity Biotech (TRIB) | Ireland | $0.015B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.011B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.011B | 0.00 |
| Flora Growth (FLGC) | United States | $0.011B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.007B | 0.00 |
| Senestech (SNES) | United States | $0.004B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.004B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.004B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |